TRAWS PHARMA INC (TRAW)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.27-11.06%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TRAW
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.5% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 189.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
TRAW — capital allocation — The shares of Common Stock that may be issued pursuant to the Purchase Agreement
Dated 2026-10-23
The shares of Common Stock that may be issued pursuant to the Purchase Agreement will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506(b) promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. This Current Report on Form 8-K shall not constitute an offer to sell o…
Why it matters: MHRA approval would let Traws start its planned flu challenge study. The study is a key step for its lead drug.
Supportive ifMHRA accepts the revised toxicology package. Traws announces approval to start the Phase 2a challenge study.
Worry ifMHRA rejects the revised package or Traws reports the resubmission slipped past Q3 2026.
Why it matters: Traws had $5.0 million in cash at June 30 and warned it may need funds after Q1 2027. Milestone warrants depend on study progress and investor action.
Worry ifThe Nov. 12 report shows cash above $5.0 million, confirms funding into Q1 2027, and reports proceeds from warrant exercises.
Less concerning ifThe Nov. 12 report shows cash below $5.0 million or says current funds no longer cover operations into Q1 2027.
Why it matters: The Oct. 23 agreement may give Traws another source of cash, but issuing shares can dilute current owners. The supplied filing summary gives no purchase limit or drawdown terms.
Watch forA company filing reports Roth purchases under the agreement. It states the cash raised and shares issued.
Also watch forA company filing reports no purchases. Or it says the agreement ended before providing cash.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$277 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $1,153 loss on $10,000 · 11.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,048 loss on $10,000 · 90.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.